CLEVELAND CLINIC HOSPITAL
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $416.4M
- Transactions
- 26,820
- Companies
- 40
- Average per transaction
- $15,524
Who reported the payments
| Eli Lilly | $34,409,406 |
| Edwards Lifesciences | $29,035,986 |
| Merck | $24,481,202 |
| E.r. Squibb & Sons, L.L.C. | $24,405,908 |
| Atricure, Inc. | $23,230,646 |
| Novartis | $18,699,474 |
| AstraZeneca | $15,081,317 |
| Genentech, Inc. | $13,460,161 |
| Pfizer | $12,605,624 |
| Biogen | $11,898,269 |
| AbbVie | $11,320,284 |
| Boston Scientific | $11,078,576 |
| Seagen Inc. | $10,614,077 |
| CSL Behring | $9,262,338 |
| Takeda Pharmaceuticals U.S.A., Inc. | $8,081,024 |
| Medtronic | $8,031,916 |
| Siemens Medical Solutions USA, Inc. | $6,652,378 |
| Regeneron | $6,556,018 |
| Bristol Myers Squibb | $6,098,937 |
| Amgen | $5,685,622 |
| Cook Incorporated | $5,536,256 |
| Janssen Research & Development, LLC | $5,480,504 |
| Jazz Pharmaceuticals Inc. | $5,241,521 |
| Abbott | $5,056,964 |
| Eisai Inc. | $4,389,150 |
| Zimmer Biomet | $3,175,695 |
| Gilead | $3,004,047 |
| Novo Nordisk AS | $2,985,237 |
| Sanofi | $2,739,280 |
| Deciphera Pharmaceuticals Inc. | $2,554,995 |
| Ventana Medical Systems, Inc. | $2,535,394 |
| Alnylam Pharmaceuticals Inc. | $2,358,187 |
| Boehringer Ingelheim | $2,293,132 |
| Beigene, Ltd. | $2,118,885 |
| Intuitive Surgical | $1,968,455 |
| Biomerieux Inc | $1,898,744 |
| Novo Nordisk | $1,843,815 |
| Incyte Corporation | $1,841,793 |
| Pharmacyclics LLC, An Abbvie Company | $1,829,580 |
| Pacira Pharmaceuticals Incorporated | $1,801,874 |